3 Reasons to Avoid NEO and 1 Stock to Buy Instead [Yahoo! Finance]
NeoGenomics Launches RaDaR ST, Expanding Molecular Residual Disease Testing Across Multiple Solid Tumor Types [Yahoo! Finance]
NeoGenomics Launches RaDaR ST, Expanding Molecular Residual Disease Testing Across Multiple Solid Tumor Types
NeoGenomics (NASDAQ:NEO) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
NeoGenomics (NASDAQ:NEO) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.